Related Experiment Video

Updated: Apr 4, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

11.2K

Treatment of drug-resistant Aspergillus infection

Maria Aigner1, Cornelia Lass-Flörl1

  • 1a Medical University of Innsbruck, Division of Hygiene and Medical Microbiology , Schöpfstrasse 41/3, 6020 Innsbruck, Austria +43 0 51 27 07 00 ; +43 0 51 27 37 00 ; cornelia.lass-floerl@i-med.ac.at.

Expert Opinion on Pharmacotherapy
|September 3, 2015
PubMed

Insights

Azole resistance in Aspergillus infections is a growing concern, leading to treatment failures. Managing azole-resistant invasive aspergillosis requires alternative strategies, as current guidelines are lacking.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Triazole antifungals are primary treatments for Aspergillus infections.
  • Emerging azole resistance is linked to treatment failures in invasive aspergillosis.
  • Lack of specific guidelines complicates the management of azole-resistant cases.

Discussion:

  • Current clinical approaches for azole-resistant invasive aspergillosis include liposomal amphotericin B or combination therapy (voriconazole/posaconazole with echinocandins).
  • Cross-resistance among azoles is frequently observed.
  • The precise role of azoles in treating azole-resistant aspergillosis is still under investigation.

Key Insights:

  • Azole resistance in Aspergillus poses a significant clinical challenge.
  • Optimizing drug exposure is crucial for successful treatment outcomes.
  • Alternative antifungal therapies are necessary for resistant infections.

Outlook:

  • Further research is needed to clarify the role of azoles in resistant cases.
  • Development of new treatment guidelines for azole-resistant invasive aspergillosis is essential.
  • Exploring novel therapeutic strategies is critical for improving patient outcomes.
Keywords:
Aspergillusantifungal treatmentaspergillosisazole resistanceposaconazolevoriconazole

More Related Videos

Isolation of Culturable Yeasts and Molds from Soils to Investigate Fungal Population Structure10:33

Isolation of Culturable Yeasts and Molds from Soils to Investigate Fungal Population Structure

Published on: May 27, 2022

7.4K
Infection of Zebrafish Larvae with Aspergillus Spores for Analysis of Host-Pathogen Interactions09:42

Infection of Zebrafish Larvae with Aspergillus Spores for Analysis of Host-Pathogen Interactions

Published on: May 16, 2020

4.6K

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
62
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
883
Fungal Phylum Ascomycota01:28

Fungal Phylum Ascomycota

Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
2.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
622